Indeed, we observed patterns of antigen coexpression on AML blasts (Fig. 2c,d) including statistically significant coexpression of U5 snRNP200 with CD47 (P = 0.002) and TIM-3 (P < 0.0001), two antigens under evaluation using separate therapeutic antibodies in phase 2–3 clinical trials for patients with AML or myelodysplastic syndrome currently21. The gene discussed is CD47; the disease is acute myeloid leukemia.